Annabelle Diot-Lemenuel
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
A cost-effectiveness analysis of reduced viral transmission with baloxavir marboxil versus oseltamivir or no treatment for seasonal and pandemic influenza management in the United Kingdom.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: June 08, 2024
Heterogeneity in the onwards transmission risk between local and imported cases affects practical estimates of the time-dependent reproduction number.
Journal: Philosophical transactions. Series A, Mathematical, physical, and engineering sciences
Published: August 15, 2022
Novel modelling approaches to predict the role of antivirals in reducing influenza transmission.
Journal: PLoS computational biology
Published: August 11, 2021
Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: April 30, 2021
Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy.
Journal: British journal of clinical pharmacology
Published: February 15, 2021
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial.
Journal: The lancet. Gastroenterology & hepatology
Published: January 07, 2021
Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B.
Journal: Hepatology (Baltimore, Md.)
Published: December 23, 2020
Reply to: 'Early HBV RNA kinetics under NA treatment may reveal new insights into HBV RNA dynamics and NA mode of action'.
Journal: Journal of viral hepatitis
Published: December 04, 2020
How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti-Hepatitis B Virus Drug.
Journal: Clinical pharmacology and therapeutics
Published: November 05, 2020
What drives the dynamics of HBV RNA during treatment?
Journal: Journal of viral hepatitis
Published: July 02, 2020
Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modelling for dosing regimen optimization.
Journal: British journal of clinical pharmacology
Published: February 12, 2020
Last Updated: 09/26/2026